Hosted on MSN22h
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC
Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Medscape1d
Talazoparib Combo Prolongs Survival in Metastatic Prostate Cancer
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Targeted Oncology2d
Talazoparib Plus Enzalutamide Extends Survival in mCRPC
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...
The American Journal of Managed Care1d
TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Cancer Therapy Advisor2d
Talazoparib Improves OS as First-Line Treatment in mCRPC
Adding talazoparib to first-line treatment with enzalutamide can improve overall survival in patients with mCRPC, phase 3 data suggest.
The American Journal of Managed Care3d
Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...
PipelineReview.com2d
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
NEW YORK, NY, USA I 13, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), ...